Evidence map›Paper›PMID 39309109›Full record

ArticleFrontiers in endocrinology2024

Non-functional alpha-cell hyperplasia with glucagon-producing NET: a case report.

Catarina Cidade-Rodrigues, Ana Paula Santos, Raquel Calheiros, Sara Santos, Catarina Matos, Ana Paula Moreira, Isabel Inácio, Pedro Souteiro, Joana Oliveira, Manuel Jácome and 4 more

Abstract readCase Reports
In one paragraph

Article in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Catarina Cidade-Rodrigues *Hospital Padre Américo, Unidade Local de Saúde do Tâmega e Sousa, Penafiel, Portugal.
Ana Paula Santos *Department of Endocrinology, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
Raquel CalheirosDepartment of Endocrinology, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
Sara SantosDepartment of Endocrinology, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
Catarina MatosHospital de Braga, Unidade Local de Saúde de Braga, Braga, Portugal.
Ana Paula MoreiraInstitute for Nuclear Sciences Applied to Health (ICNAS), University of Coimbra, Coimbra, Portugal.
Isabel InácioDepartment of Endocrinology, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
Pedro SouteiroDepartment of Endocrinology, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
Joana OliveiraDepartment of Endocrinology, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
Manuel JácomeDepartment of Pathology, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
Sofia S PereiraUnit for Multidisciplinary Research in Biomedicine (UMIB), School of Medicine and Biomedical Sciences (ICBAS), University of Porto, Porto, Portugal.
Rui HenriqueResearch Center of IPO Porto (CI-IPOP), RISE@CI-IPO (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto), Porto Comprehensive Cancer Centre (P.CCC), Porto, Portugal.
Isabel Torres *Department of Endocrinology, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
Mariana P Monteiro *Unit for Multidisciplinary Research in Biomedicine (UMIB), School of Medicine and Biomedical Sciences (ICBAS), University of Porto, Porto, Portugal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Alpha-cell hyperplasia (ACH) is a rare pancreatic endocrine condition. Three types of ACH have been described: functional or nonglucagonoma hyperglucagonemic glucagonoma syndrome, reactive or secondary to defective glucagon signaling, and non-functional. Few cases of ACH with concomitant pancreatic neuroendocrine tumors (pNETs) have been reported and its etiology remains poorly understood. A case report of non-functional ACH with glucagon-producing NET is herein presented. Case report: A 72-year-old male was referred to our institution for a 2 cm single pNET incidentally found during imaging for acute cholecystitis. The patient's past medical history included type 2 diabetes (T2D) diagnosed 12 years earlier, for which he was prescribed metformin, dapagliflozin, and semaglutide. The pNET was clinically and biochemically non-functioning, apart from mildly elevated glucagon 217 pg/ml (<209), and Discussion and conclusion: This case reports the incidental finding of a clinically non-functioning pNET in a patient with T2D and elevated glucagon levels, unexpectedly diagnosed as glucagon-producing NET and ACH. A high level of suspicion was required to conduct the glucagon immunostaining, which is not part of the pathology routine for a clinically non-functioning pNET, and was key for the diagnosis that otherwise would have been missed. This case highlights the need to consider the diagnosis of glucagon-producing pNET on an ACH background even in the absence of glucagonoma syndrome.

Indexed as

GlucagonGlucagon-Secreting CellsHyperplasiaNeuroendocrine TumorsPancreatic NeoplasmsAgedDiabetes Mellitus, Type 2HumansMaleGlucagonalpha-cellglucagon-producing NEThyperplasianeuroendocrine tumorspancreas

Identifiers

PMID39309109
PMCPMC11412808

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.